Chiome Bioscience Inc. Logo

Chiome Bioscience Inc.

Clinical-stage biotech developing therapeutic antibodies and providing R&D services to partners.

4583 | T

Overview

Corporate Details

ISIN(s):
JP3205350006
LEI:
Country:
Japan
Address:
渋谷区本町三丁目12番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chiome Bioscience Inc. is a clinical-stage biotechnology company established in 2005, specializing in the research and development of therapeutic antibodies. The company focuses on addressing unmet medical needs by creating innovative antibody-based drugs. It utilizes a portfolio of proprietary technologies, most notably its ADLib® system, to accelerate the discovery and selection of optimal antibody candidates for its drug pipeline. Chiome Bioscience is engaged in advancing its own therapeutic programs and providing antibody development support and services to partners in the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-12 09:05
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-08-12 09:04
Interim Report
半期報告書-第22期(2025/01/01-2025/12/31)
Japanese 188.7 KB
2025-03-28 08:09
Governance Information
内部統制報告書-第21期(2024/01/01-2024/12/31)
Japanese 22.8 KB
2025-03-28 08:07
Registration Form
確認書
Japanese 8.3 KB
2025-03-28 08:05
Annual Report
有価証券報告書-第21期(2024/01/01-2024/12/31)
Japanese 1.6 MB
2025-03-28 08:03
Post-Annual General Meeting Information
臨時報告書
Japanese 30.6 KB
2025-02-19 08:04
Audit Report / Information
臨時報告書
Japanese 19.7 KB
2024-11-15 07:48
Registration Form
確認書
Japanese 8.4 KB
2024-11-15 07:45
Annual Report
訂正有価証券報告書-第20期(2023/01/01-2023/12/31)
Japanese 767.5 KB
2024-08-13 09:10
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-08-13 09:08
Interim Report
半期報告書-第21期(2024/01/01-2024/12/31)
Japanese 226.8 KB
2024-07-05 08:02
Registration Form
有価証券届出書(組込方式)
Japanese 264.6 KB
2024-05-14 09:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/01/01-2024/03/31)
Japanese 185.2 KB
2024-05-14 09:12
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-03-26 08:50
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB

Automate Your Workflow. Get a real-time feed of all Chiome Bioscience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chiome Bioscience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chiome Bioscience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.